Anker SD, Butler J, Filippatos G, et al. - Patients with heart failure and a preserved ejection fraction experienced a decrease in the combined risk of cardiovascular death or hospitalization for heart failure, irrespective of the presence or absence of diabetes, when treated with empagliflozin.

• This double-blind trial involved 5,988 patients with class II–IV heart failure and an ejection fraction of more than 40%.

• Patients were randomized to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy.

• A composite of cardiovascular death or hospitalization for heart failure was the primary outcome.

• Occurrence of a primary outcome event was evident in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79).

• This impact was primarily associated with a lower risk of hospitalization for heart failure in the empagliflozin group.

• Empagliflozin’s impacts seemed consistent in patients with or without diabetes.

• The empagliflozin group had a lower total number of hospitalizations for heart failure vs placebo group.

• Empagliflozin was more frequently associated with uncomplicated genital and urinary tract infections and hypotension.